Orchestra BioMed Holdings, Inc. Net Income
Orchestra BioMed Holdings, Inc. (OBIO) reported Net Income of -$23.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$23.75M.
- Orchestra BioMed Holdings, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$20.69M.
- Orchestra BioMed Holdings, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $6.25M.
- Orchestra BioMed Holdings, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$20.83M.
- Orchestra BioMed Holdings, Inc. net income (loss) attributable to parent for fiscal 2025 was -$52.70M.
- Orchestra BioMed Holdings, Inc. net income (loss) attributable to parent for fiscal 2024 was -$61.02M.
- Orchestra BioMed Holdings, Inc. net income (loss) attributable to parent for fiscal 2023 was -$49.12M.
- Orchestra BioMed Holdings, Inc. net income (loss) attributable to parent for fiscal 2022 was -$33.61M.
| Period end | Net Income (Loss) Attributable to Parent 1 month | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 4 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 7 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$23.75M 10-Q · filed 2026-08-10 | -$44.45M 10-Q · filed 2026-08-10 | -$38.20M derived: sum of 3 quarters · filed 2026-08-10 | -$59.03M derived: sum of 4 quarters · filed 2026-08-10 | |||||||
| 2026-03-31 | -$20.69M 10-Q · filed 2026-08-10 | -$14.45M derived: sum of 2 quarters · filed 2026-08-10 | -$35.27M derived: sum of 3 quarters · filed 2026-08-10 | -$54.64M derived: sum of 4 quarters · filed 2026-08-10 | |||||||
| 2025-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$14.58M derived: sum of 2 quarters · filed 2026-03-12 | -$33.95M derived: sum of 3 quarters · filed 2026-08-10 | -$52.70M 10-K · filed 2026-03-12 | |||||||
| 2025-09-30 | -$20.83M 10-Q · filed 2025-11-10 | -$40.19M derived: sum of 2 quarters · filed 2026-08-10 | -$58.95M 10-Q · filed 2025-11-10 | -$75.10M derived: sum of 4 quarters · filed 2026-08-10 | |||||||
| 2025-06-30 | -$19.36M 10-Q · filed 2026-08-10 | -$38.12M 10-Q · filed 2026-08-10 | -$54.27M derived: sum of 3 quarters · filed 2026-08-10 | -$69.70M derived: sum of 4 quarters · filed 2026-08-10 | |||||||
| 2025-03-31 | -$18.75M 10-Q · filed 2026-08-10 | -$34.91M derived: sum of 2 quarters · filed 2026-08-10 | -$50.34M derived: sum of 3 quarters · filed 2026-08-10 | -$66.32M derived: sum of 4 quarters · filed 2026-08-10 | |||||||
| 2024-12-31 | -$16.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$31.58M derived: sum of 2 quarters · filed 2026-03-12 | -$47.56M derived: sum of 3 quarters · filed 2026-03-12 | -$61.02M 10-K · filed 2026-03-12 | |||||||
| 2024-09-30 | -$15.43M 10-Q · filed 2025-11-10 | -$31.41M derived: sum of 2 quarters · filed 2025-11-10 | -$44.87M 10-Q · filed 2025-11-10 | -$57.69M derived: sum of 4 quarters · filed 2025-11-10 | |||||||
| 2024-06-30 | -$15.98M 10-Q · filed 2025-11-10 | -$29.44M 10-Q · filed 2025-08-12 | -$42.26M derived: sum of 3 quarters · filed 2025-11-10 | -$55.58M derived: sum of 4 quarters · filed 2025-11-10 | |||||||
| 2024-03-31 | -$13.46M 10-Q · filed 2025-11-10 | -$26.28M derived: sum of 2 quarters · filed 2025-11-10 | -$39.60M derived: sum of 3 quarters · filed 2025-11-10 | -$51.64M derived: sum of 4 quarters · filed 2025-11-10 | |||||||
| 2023-12-31 | -$12.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$26.13M derived: sum of 2 quarters · filed 2025-03-31 | -$38.18M derived: sum of 3 quarters · filed 2025-03-31 | -$49.12M 10-K · filed 2025-03-31 | |||||||
| 2023-09-30 | -$13.32M 10-Q · filed 2024-11-12 | -$25.36M derived: sum of 2 quarters · filed 2024-11-12 | -$36.30M 10-Q · filed 2024-11-12 | -$46.05M derived: sum of 4 quarters · filed 2024-11-12 | |||||||
| 2023-06-30 | -$12.05M 10-Q · filed 2024-11-12 | -$22.99M 10-Q · filed 2024-08-12 | -$32.74M derived: sum of 3 quarters · filed 2024-11-12 | -$43.02M derived: sum of 4 quarters · filed 2024-11-12 | |||||||
| 2023-03-31 | -$10.94M 10-Q · filed 2024-11-12 | -$20.69M derived: sum of 2 quarters · filed 2024-11-12 | -$30.97M derived: sum of 3 quarters · filed 2024-11-12 | -$38.82M derived: sum of 4 quarters · filed 2024-11-12 | |||||||
| 2022-12-31 | -$9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$20.03M derived: sum of 2 quarters · filed 2024-03-27 | -$27.88M derived: sum of 3 quarters · filed 2024-03-27 | -$33.61M 10-K · filed 2024-03-27 | -$2.74M 10-K · filed 2023-01-25 | ||||||
| 2022-09-30 | -$10.28M 10-Q · filed 2023-11-13 | -$685.79K 10-Q · filed 2022-11-14 | -$18.13M derived: sum of 2 quarters · filed 2023-11-13 | -$23.86M 10-Q · filed 2023-11-13 | -$1.86M 10-Q · filed 2022-11-14 | -$23.95M derived: sum of 4 quarters · filed 2023-11-13 | |||||
| 2022-06-30 | -$7.85M 10-Q · filed 2023-11-13 | -$734.92K 10-Q · filed 2022-08-15 | -$13.58M 10-Q · filed 2023-08-10 | -$1.17M 10-Q · filed 2022-08-15 | -$13.66M derived: sum of 3 quarters · filed 2023-11-13 | -$13.75M derived: sum of 4 quarters · filed 2023-11-13 | |||||
| 2022-03-31 | -$5.73M 10-Q · filed 2023-11-13 | -$437.69K 10-Q · filed 2022-05-13 | -$5.82M derived: sum of 2 quarters · filed 2023-11-13 | -$5.91M derived: sum of 3 quarters · filed 2023-11-13 | -$6.00M derived: sum of 4 quarters · filed 2023-11-13 | ||||||
| 2021-12-31 | -$88.01K derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-25 | -$178.42K derived: sum of 2 quarters · filed 2023-01-25 | -$270.75K derived: sum of 3 quarters · filed 2023-01-25 | -$378.75K 10-K · filed 2023-01-25 | |||||||
| 2021-09-30 | -$90.41K 10-Q · filed 2022-11-14 | -$182.74K derived: sum of 2 quarters · filed 2022-11-14 | -$290.74K 10-Q · filed 2022-11-14 | ||||||||
| 2021-06-30 | -$92.33K 10-Q · filed 2022-11-14 | -$200.33K 10-Q · filed 2022-08-15 | |||||||||
| 2021-03-31 | -$108.00K 10-Q · filed 2022-11-14 | ||||||||||
| 2020-12-31 | -$173.54K 10-K/A · filed 2022-03-31 | ||||||||||
| 2020-09-30 | -$66.21K 10-Q/A · filed 2022-03-31 | -$81.43K 10-Q/A · filed 2022-03-31 | |||||||||
| 2020-06-30 | -$15.21K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |